Medimpex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 44 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
About Medimpex Pharmaceuticals
Medimpex Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 July 1980 and has a history of 44 years and seven months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Surendra Jangir and Padmakar Sawant serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1980PTC022801
-
Company No.
022801
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Jul 1980
-
Date of AGM
29 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Medimpex Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surendra Jangir
|
Director | 05-Nov-2011 | Current |
|
Padmakar Sawant
|
Director | 01-Mar-2007 | Current |
Financial Performance of Medimpex Pharmaceuticals.
Medimpex Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medimpex Pharmaceuticals?
In 2017, Medimpex Pharmaceuticals had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Wavin India LimitedSurendra Jangir is a mutual person
-
Walter Bushnell Medicines Private LimitedSurendra Jangir is a mutual person
-
Walter Bushnell Pharmaceuticals Private LimitedSurendra Jangir is a mutual person
-
Walter Bushnell Drugs Private LimitedSurendra Jangir and Padmakar Sawant are mutual person
-
Walter Bushnell Medicaid Private LimitedPadmakar Sawant is a mutual person
-
Walter Bushnell Medinova Private LimitedSurendra Jangir is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medimpex Pharmaceuticals?
Unlock and access historical data on people associated with Medimpex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medimpex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medimpex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
